Etravirine (Intelence, TMC125): News & Research
- Intelence (Etravirine) Labeling Updates (March 1, 2013)
From U.S. Food and Drug Administration
- Darunavir/Ritonavir and Etravirine as a Prevention Method Is Biologically Plausible (Summer 2012)
To read PDF, click here.
In Being Alive Newsletter, from Being Alive
On TheBodyPRO.com
- Intelence Now for Kids Ages 6 and Older (May/June 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Intelence (Etravirine): Pediatric Dosing Recommendations and New Scored 25 mg Tablet for Pediatric Dosing (March 26, 2012)
From U.S. Food and Drug Administration
- Etravirine 200-mg Formulation Available in UK (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily (May/June 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- MSF Letter Criticizes Johnson & Johnson for Not Joining Medicines Patent Pool (April 26, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Newly Approved Intelence (Etravirine) Dose May Halve Pill Burden (December 23, 2010)
From U.S. Food and Drug Administration
- Switch From Sustiva to Intelence Reduces Central Nervous System Side Effects (July 20, 2010)
From AIDSmeds.com
- Intelence (Etravirine) Label Revised to Include New Drug-Drug Interaction Information (March 11, 2010)
From U.S. Food and Drug Administration
- New Warning of Serious Intelence Side Effect (February 2010)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- FDA Grants Full Approval to J&J's HIV Drug (December 8, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Intelence (Etravirine) Label Updated to Reflect Dosing Data Through 48 Weeks (November 25, 2009)
From U.S. Food and Drug Administration
- Information for Health Care Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Health Care Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC) (November 17, 2009)
From U.S. Food and Drug Administration
- Tibotec, FDA Update Warning Label on HIV Drug's Risk of Severe Skin Reaction (August 27, 2009)
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- New FDA Report Suggests Possible Link Between Intelence and Joint Problems (September 8, 2008)
From Associated Press
- AAHIVM Encouraged by TMC125 Approval (January 22, 2008)
New HIV medication could offer more options for treatment-experienced patients.
From American Academy of HIV Medicine
- Fair Pricing Coalition Lauds Pricing of New Tibotec Drug (January 21, 2008)
From Fair Pricing Coalition
- FDA Receives New Drug Application for TMC125 (Etravirine) (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Adding Etravirine to Prezista Improves Anti-HIV Activity, Studies Show (July 6, 2007)
From aidsmap.com
|
Advertisement
|
Email
Glossary
